Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
| Revenue (Most Recent Fiscal Year) | $64.17B |
| Net Income (Most Recent Fiscal Year) | $17.12B |
| PE Ratio (Current Year Earnings Estimate) | 8.86 |
| PE Ratio (Trailing 12 Months) | 10.34 |
| PEG Ratio (Long Term Growth Estimate) | 0.72 |
| Price to Sales Ratio (Trailing 12 Months) | 3.10 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.31 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 8.34 |
| Pre-Tax Margin (Trailing 12 Months) | 31.07% |
| Net Margin (Trailing 12 Months) | 26.67% |
| Return on Equity (Trailing 12 Months) | 44.44% |
| Return on Assets (Trailing 12 Months) | 17.17% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.36 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.15 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.74 |
| Inventory Turnover (Trailing 12 Months) | 2.40 |
| Book Value per Share (Most Recent Fiscal Quarter) | $18.33 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.72 |
| Earnings per Share (Most Recent Fiscal Year) | $7.65 |
| Diluted Earnings per Share (Trailing 12 Months) | $6.73 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Common Shares Outstanding | 2.52B |
| Free Float | 2.52B |
| Market Capitalization | $199.14B |
| Average Volume (Last 20 Days) | 15.69M |
| Beta (Past 60 Months) | 0.40 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.09% |
| Percentage Held By Institutions (Latest 13F Reports) | 76.07% |
| Annual Dividend (Based on Last Quarter) | $3.24 |
| Dividend Yield (Based on Last Quarter) | 4.10% |